RaQualia Pharma (TSE:4579) Cyclically Adjusted Revenue per Share: 円95.58 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4579 RaQualia Pharma Inc TSE:4579
54 GF Score
Price 円453.00
GF Value 円310.66
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is RaQualia Pharma Cyclically Adjusted Revenue per Share?

RaQualia Pharma TSE:4579 -0.44% 54 Cyclically Adjusted Revenue per Share is 円95.58 as of Mar. 2026. GuruFocus rates TSE:4579 with a GF Score™ of 54/100 and a GF Value™ of 円310.66 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

RaQualia Pharma's adjusted revenue per share for the three months ended in Mar. 2026 was 円31.410. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円95.58 for the trailing ten years ended in Mar. 2026.

During the past 12 months, RaQualia Pharma's average Cyclically Adjusted Revenue Growth Rate was 12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of RaQualia Pharma was 16.70% per year. The lowest was 16.70% per year. And the median was 16.70% per year.

As of today (2026-07-26), RaQualia Pharma's current stock price is 円453.00. RaQualia Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円95.58. RaQualia Pharma's Cyclically Adjusted PS Ratio of today is 4.74.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of RaQualia Pharma was 30.28. The lowest was 3.92. And the median was 13.04.


RaQualia Pharma  (TSE:4579) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

RaQualia Pharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=453.00/95.58
=4.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of RaQualia Pharma was 30.28. The lowest was 3.92. And the median was 13.04.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


RaQualia Pharma Cyclically Adjusted Revenue per Share Related Terms


RaQualia Pharma Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Cyclically Adjusted Revenue per Share Chart

RaQualia Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 49.25 61.23 69.81 0.00 0.00

RaQualia Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 84.65 87.57 0.00 0.00 95.58

TSE:4579 vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, RaQualia Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RaQualia Pharma Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where RaQualia Pharma's Cyclically Adjusted PS Ratio falls into.


TSE:4579
54GF Score
RaQualia Pharma Inc TSE:4579
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaQualia Pharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, RaQualia Pharma's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=31.41/112.7000*112.7000
=31.410

Current CPI (Mar. 2026) = 112.7000.

RaQualia Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 32.216 97.900 37.086
201606 0.666 98.100 0.765
201609 1.146 98.000 1.318
201612 3.551 98.400 4.067
201703 21.907 98.100 25.167
201706 2.378 98.500 2.721
201709 7.398 98.800 8.439
201712 40.068 99.400 45.429
201803 19.497 99.200 22.150
201806 2.427 99.200 2.757
201809 4.266 99.900 4.813
201812 10.384 99.700 11.738
201903 17.059 99.700 19.283
201906 9.572 99.800 10.809
201909 7.859 100.100 8.848
201912 47.485 100.500 53.249
202003 5.897 100.300 6.626
202006 11.894 99.900 13.418
202009 9.585 99.900 10.813
202012 25.475 99.300 28.913
202103 31.291 99.900 35.300
202106 31.742 99.500 35.953
202109 14.372 100.100 16.181
202112 55.027 100.100 61.953
202203 16.189 101.100 18.046
202206 52.825 101.800 58.481
202209 21.773 103.100 23.800
202212 48.248 104.100 52.234
202303 17.172 104.400 18.537
202306 29.772 105.200 31.895
202309 22.270 106.200 23.633
202312 18.763 106.800 19.800
202403 29.995 107.200 31.534
202406 35.237 108.200 36.702
202412 0.000 110.700 0.000
202503 44.430 111.100 45.070
202506 24.909 111.700 25.132
202509 0.000 112.000 0.000
202512 0.000 113.000 0.000
202603 31.410 112.700 31.410

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円95.58 mean?
RaQualia Pharma (TSE:4579) has a Cyclically Adjusted Revenue per Share of 円95.58 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on RaQualia Pharma and its competitors.
Is RaQualia Pharma's Cyclically Adjusted Revenue per Share too high?
RaQualia Pharma's current Cyclically Adjusted Revenue per Share is 円95.58. Overall, RaQualia Pharma has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
RaQualia Pharma's Cyclically Adjusted Revenue per Share of 円95.58 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on RaQualia Pharma and its competitors. RaQualia Pharma's current Cyclically Adjusted Revenue per Share is 円95.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Overvalued. The stock's GF Value™ is 円310.66, compared to a current price of 円453.00 — trading 45.8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円95.58. RaQualia Pharma's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Cyclically Adjusted Revenue per Share is 円95.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be overvalued. The current stock price of 円453.00 is trading 45.8% above its estimated GF Value™ of 円310.66. GuruFocus considers RaQualia Pharma to be Significantly Overvalued.

Key valuation signals for TSE:4579:

  • Cyclically Adjusted Revenue per Share: 円95.58
  • GF Value™: 円310.66 vs. price of 円453.00 (45.8% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
54GF Score

Get the complete analysis for TSE:4579

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円453.00
Price
円310.66
GF Value